Table 6: Effects on blood safety indicators (X ± SD) in study patients.
|
Treatment |
Baseline |
12 weeks |
|
|
Alanine amino transferase (ALAT) (U/L) |
|
|
Policosanol |
23.45 ± 8.88 |
22.35 ± 13.20 |
|
Placebo |
22.19 ± 9.21 |
22.00 ± 10.40 |
|
|
Aspartate amino transferase (ASAT) (U/L) |
|
|
Policosanol |
24.11 ± 10.84 |
26.96 ± 15.70 |
|
Placebo |
24.07 ± 8.62 |
26.16 ± 11.20 |
|
|
Glucose (mmol/L) |
|
|
Policosanol |
5.16 ± 1.52 |
4.57 ± 1.10* |
|
Placebo |
5.04 ± 0.88 |
4.48 ± 0.70*** |
|
|
Creatinine (µmol/L) |
|
|
Policosanol |
73.75 ± 14.94 |
74.56 ± 15.60 |
|
Placebo |
73.41 ± 13.90 |
75.72 ± 14.20 |
|
|
Uric acid (µmol/L) |
|
|
Policosanol |
286.83 ± 62.29 |
327.09 ± 77.80** |
|
Placebo |
287.85 ± 62.70 |
335.43 ± 82.60** |
X mean, SD standard deviation
*p < 0.05, **p < 0.01, ***p < 0.001 Comparison with baseline (McNemar test)